Bardy Diagnostics™ Achieves Milestone of 40,000 Patients Monitored by the Carnation Ambulatory Monitor


SEATTLE,  /PRNewswire/ -- Bardy Diagnostics, Inc., ("BardyDx"), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has achieved a significant year-end milestone of monitoring over 40,000 patients driven by rapid adoption of the Carnation Ambulatory Monitor ("CAM™"), the world's first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

We're close to your heart(TM)

"Product acceptance continues to rapidly grow, supported by the positive customer reception to the CAM's unique P-wave centric technology," said Ken Nelson, Chief Commercial Officer. "With over 40,000 patients to date having benefited from the CAM patch, it is evident to our customers that P-wave specificity is essential for accurately diagnosing arrhythmias and determining appropriate medical or procedural intervention."

The significance of the CAM patch's P-wave focused clinical value was recently highlighted in the September 2018 issue of the American Heart Journal that published the results of a head-to-head comparison with the iRhythm Zio® XT patch. The study, "Comparison of two ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity," concluded that the BardyDx CAM patch identified 40% more arrhythmias and resulted in better, more informed clinical decision-making in 41% of patients over the iRhythm Zio® XT patch. In addition, an abstract presented at the 2018 American Heart Association Scientific Sessions in November titled, "P-Wave Centric Patch Monitors May Reduce Need for Implantable Monitors Following Cryptogenic Stroke," suggested that the P-wave centric CAM patch should be used first to detect atrial fibrillation in cryptogenic stroke patients before the decision to implant an implantable loop recorder (ILR).

"Customers are voicing their excitement about finally having access to a diagnostic tool that is able to accurately and precisely identify arrhythmia type," said BardyDx Founder and Chief Executive Officer, Gust H Bardy, MD. "We are excited to surpass this noteworthy record and look forward to impacting even more patient lives with our pioneering technology."

The milestone builds upon the growing market recognition of the innovative P-wave centric features of the CAM patch. Most recently, BardyDx was selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma and was also named winner of the Children's National Health System Pediatric Medical Device Innovation Competition for the CAM's unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was recently awarded an Innovative Technology contract with Vizient, Inc. upon recommendation of its member-led council of hospital experts for the CAM patch's ability to enhance clinical care and patient safety.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company's CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at

Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.



Cision View original content to download multimedia:

SOURCE Bardy Diagnostics, Inc.


Back to news